Icosapent ethyl lowers risk of CV events in CAD patients on statins: RESPECT-EPA trial

Japan: Using icosapent ethyl, a purified eicosapentaenoic acid (EPA), alongside statin therapy, may reduce the risk of adverse cardiovascular events in chronic coronary artery disease (CAD) patients,...

Related Keywords

Japan ,United States ,Chicago ,Illinois ,Japanese ,American ,Hiroyuki Daida ,Scientific Session Of The American Heart Association ,Scientific Sessions Of The American Heart Association ,American Heart Association ,Scientific Sessions ,Eicosapentaenoic Acid ,Icosapent Ethyl ,Coronary Artery Disease ,Cardiovascular Events ,Myocardial Infarction ,Stroke ,Cardiovascular Disease ,Unstable Angina ,Death ,Ardiovascular ,Arachidonic Acid ,